Tenderwize
Wróć do wyszukiwania

Non-exclusive Drug Discount Agreement for Fluorouracil (ATC L01BC02 / D11AF05)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 338 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fluorouracil (ATC-Code nach WHO: L01BC02; amtlicher ATC-Code: D11AF05)

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

30 / 100

Czynniki ryzyka

No minimum purchase quantities; actual demand is uncertain and entirely dependent on prescribing and dispensing pattern...

The buyer may end the Open-House procedure if exclusive agreements are signed, which typically occur 8-12 months after...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Conclusion of non-exclusive discount agreements for Fluorouracil medicinal products
  • Open-House model – any interested pharmaceutical company that meets the conditions can participate
Pokaż pełne podsumowanie

This is a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active ingredient Fluorouracil, using an Open-House model. The AOK PLUS health insurance fund invites all interested pharmaceutical companies to participate without negotiation or exclusivity. The agreement runs until 31 July 2027. No minimum purchase quantities are guaranteed. The procedure is published for transparency purposes and is not a classic public procurement. All communication and document exchange occurs via the DTVP portal. Strict confidentiality applies. First submission deadline for contracts starting 1 August 2025 is 23 June 2025; subsequent deadlines are specified in a separate schedule.

Ryzyka

No minimum purchase quantities; actual demand is uncertain and entirely dependent on prescribing and dispensing pattern...

The buyer may end the Open-House procedure if exclusive agreements are signed, which typically occur 8-12 months after...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical manufacturer as defined in § 4(18) AMG with respect to the offered products

Eligibility

  • Must submit a self-declaration on absence of exclusion grounds (§§ 123, 124 GWB)

Administrative

  • Must submit a self-declaration regarding Russia sanctions (EU Regulation 833/2014)

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Fluorouracil (ATC L01BC02 / D11AF05)

Non-exclusive discount agreement for fluorouracil-containing medicinal products. Single lot open to all qualified pharmaceutical manufacturers. No guaranteed volumes or exclusivity.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jun 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Expired Jun 23, 2025

Szczegóły zamówienia

Data publikacji
29 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
348750-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3